We are conducting system maintenance, which may temporarily affect some services and our ability to answer phone calls. For urgent queries, please contact us via email using the addresses on our contact page. We appreciate your patience and are working to restore full services promptly. Thank you for your cooperation!
0
Signin
countryflagUS

18889881171

MSFT 417.83 -0.6798% AAPL 226.85 0.2829% NVDA 118.714 1.465% GOOGL 165.686 -0.7809% GOOG 167.125 -0.7689% AMZN 185.38 0.135% META 573.28 -0.5534% AVGO 171.45 2.3765% TSLA 249.36 -3.3563% TSM 175.7 2.1096% LLY 890.255 0.6529% V 276.22 -0.4971% JPM 207.51 0.227% UNH 592.97 1.6578% NVO 116.255 -1.4872% WMT 80.19 -1.3289% LVMUY 147.83 0.2441% XOM 120.8281 0.7489% LVMHF 740.0 0.955% MA 495.19 -0.2397%

Comera Life Sciences Holdings Inc

Healthcare US CMRAW

NoneUSD
-(-%)

Last update at 2024-04-11T21:01:14.069993Z

Day Range

--
LowHigh

52 Week Range

0.00030.07
LowHigh

Fundamentals

  • Previous Close 0.0008
  • Market Cap0.00000M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.54698M
  • Revenue TTM1.00M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-6.08

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -18.00410M -5.45178M -2.12549M
Minority interest - - -
Net income -24.03818M -5.29119M -2.12549M
Selling general administrative 10.65M 3.94M 1.20M
Selling and marketing expenses - - -
Gross profit 0.42M 0.16M 0.34M
Reconciled depreciation 0.09M 0.09M 0.09M
Ebit -11.97002M -5.53563M -2.12752M
Ebitda -13.33181M -5.61008M -2.03777M
Depreciation and amortization -1.36180M -0.07445M 0.09M
Non operating income net other - - -
Operating income -11.97002M -5.53563M -2.12752M
Other operating expenses 12.60M 5.86M 2.57M
Interest expense 0.02M 0.16M 0.00000M
Tax provision - - -
Interest income - - -
Net interest income -0.02039M - -
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 6.03M -0.16059M -0.00203M
Total revenue 0.63M 0.32M 0.44M
Total operating expenses 12.39M 5.69M 2.47M
Cost of revenue 0.21M 0.16M 0.10M
Total other income expense net -6.03408M 0.08M 0.00203M
Discontinued operations - - -
Net income from continuing ops -18.00410M -5.45178M -2.12549M
Net income applicable to common shares - - -
Preferred stock and other adjustments - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Total assets 3.73M 7.42M 0.55M
Intangible assets - - -
Earning assets - - -
Other current assets 0.07M 0.05M 0.02M
Total liab 9.97M 22.10M 0.39M
Total stockholder equity -6.24709M -14.68625M 0.15M
Deferred long term liab - - -
Other current liab 2.80M 0.00791M 0.00139M
Common stock 0.00167M 0.00003M 10.68M
Capital stock 0.00167M 0.00040M 10.68M
Retained earnings -34.90392M -16.89982M -11.44805M
Other liab - - -
Good will - - -
Other assets - - -
Cash 0.45M 6.51M 0.16M
Cash and equivalents - - -
Total current liabilities 5.06M 1.05M 0.23M
Current deferred revenue 0.14M 0.50M 0.03M
Net debt 0.33M -6.18708M 0.00516M
Short term debt 0.65M 0.12M 0.11M
Short long term debt 0.46M - -
Short long term debt total 0.78M 0.32M 0.16M
Other stockholder equity -4489.05484M 2.21M 0.92M
Property plant equipment - - -
Total current assets 3.06M 6.78M 0.31M
Long term investments - - -
Net tangible assets - - -
Short term investments - - -
Net receivables 0.03M 0.22M 0.12M
Long term debt - - 0.16M
Inventory 2.51M 0.00200M 0.02M
Accounts payable 1.46M 0.42M 0.10M
Total permanent equity - - -
Noncontrolling interest in consolidated entity - - -
Temporary equity redeemable noncontrolling interests - - -
Accumulated other comprehensive income - - -
Additional paid in capital - - -
Common stock total equity - - -
Preferred stock total equity - - -
Retained earnings total equity - - -
Treasury stock - - -
Accumulated amortization - - -
Non currrent assets other 0.09M 0.08M 0.06M
Deferred long term asset charges - - -
Non current assets total 0.66M 0.64M 0.24M
Capital lease obligations 0.32M 0.32M 0.00000M
Long term debt total - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -0.02861M -0.14201M -0.01237M
Change to liabilities - - -
Total cashflows from investing activities - - -
Net borrowings - - -
Total cash from financing activities 5.24M 10.28M 1.55M
Change to operating activities - - -
Net income -18.00410M -5.45178M -2.12549M
Change in cash -4.55791M 6.38M -0.26414M
Begin period cash flow 6.56M 0.18M 0.44M
End period cash flow 2.00M 6.56M 0.18M
Total cash from operating activities -9.77177M -3.75795M -1.80410M
Issuance of capital stock 0.83M 9.35M 1.39M
Depreciation 0.09M 0.09M 0.09M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - 0.17M 0.08M
Change to account receivables -0.03432M 0.11M -0.11307M
Sale purchase of stock 650.00M - -
Other cashflows from financing activities -645.58700M -0.14201M 0.16M
Change to netincome - - -
Capital expenditures 0.03M 0.14M 0.01M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 2.55M 0.57M -0.04190M
Stock based compensation 0.38M 1.11M 0.10M
Other non cash items 5.21M 0.08M 0.17M
Free cash flow -9.80038M -3.89996M -1.81647M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
CMRAW
Comera Life Sciences Holdings Inc		 - -% - - - - -
NVO
Novo Nordisk A/S		 -1.755 1.49% 116.25 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.06 1.74% 116.20 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.275 1.55% 462.49 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -4.415 0.42% 1042.49 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Comera Life Sciences Holdings Inc

12 Gill Street, Woburn, MA, United States, 01801

Key Executives

Name Title Year Born
Mr. Jeffrey S. Hackman Chairman, Pres & CEO 1960
Dr. Neal I. Muni M.D., MSPH Exec. VP & COO 1974
Dr. Robert P. Mahoney Ph.D. Chief Scientific Officer, VP of R&D and Member of Advisory Board 1965
Mr. Michael G. Campbell CPA Interim Chief Financial Officer 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.